Market Cap | 12.91B | P/E | 48.82 | EPS this Y | 6.80% | Ern Qtrly Grth | -46.20% |
Income | 168.07M | Forward P/E | 34.17 | EPS next Y | 15.30% | 50D Avg Chg | 1.00% |
Sales | 1.16B | PEG | 3.68 | EPS past 5Y | 11.95% | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 6.83 | EPS next 5Y | 11.25% | 52W High Chg | -16.00% |
Recommedations | 1.90 | Quick Ratio | 2.47 | Shares Outstanding | 158.65M | 52W Low Chg | 21.00% |
Insider Own | 1.02% | ROA | 5.74% | Shares Float | 156.82M | Beta | 1.27 |
Inst Own | 100.17% | ROE | 8.33% | Shares Shorted/Prior | 3.70M/2.95M | Price | 82.02 |
Gross Margin | 66.47% | Profit Margin | 14.50% | Avg. Volume | 914,012 | Target Price | 83.32 |
Oper. Margin | 22.44% | Earnings Date | Oct 29 | Volume | 1,280,237 | Change | -0.10% |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kummeth Charles R. | Chief Executive Offi.. Chief Executive Officer | Jul 21 | Sell | 88.3628 | 80,000 | 7,069,024 | 1,258,766 | 07/25/23 |
Kummeth Charles R. | Chief Executive Offi.. Chief Executive Officer | Jun 30 | Option | 26.65 | 616,676 | 16,434,415 | 1,729,493 | 07/05/23 |
Kelderman Kim | Pres. Diagnostics &.. Pres. Diagnostics & Genom | Aug 23 | Option | 150.78 | 663 | 99,967 | 3,801 | 08/25/22 |
Furlow Brenda S. | SVP - General Counse.. SVP - General Counsel | Aug 08 | Option | 177.32 | 563 | 99,831 | 6,523 | 08/10/22 |
Kummeth Charles R. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jul 28 | Option | 108.49 | 45,346 | 4,919,588 | 262,749 | 08/01/22 |
Kummeth Charles R. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jul 06 | Option | 108.49 | 50,000 | 5,424,500 | 248,338 | 07/08/22 |
HIGGINS JOHN L | Director Director | Jun 07 | Option | 66.9 | 1,600 | 107,040 | 5,206 | 06/09/22 |
HIGGINS JOHN L | Director Director | Jun 07 | Sell | 365.2 | 1,600 | 584,320 | 4,606 | 06/09/22 |
Kummeth Charles R. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 07 | Option | 108.49 | 5,104 | 553,733 | 203,442 | 06/09/22 |
Kummeth Charles R. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 07 | Sell | 365 | 5,104 | 1,862,960 | 198,338 | 06/09/22 |
BAUMGARTNER ROBERT V | Director Director | May 10 | Buy | 352.55 | 300 | 105,765 | 10,106 | 05/11/22 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Nov 01 | Option | 125.05 | 9,022 | 1,128,201 | 10,955 | 11/03/21 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Nov 01 | Sell | 526.65 | 9,022 | 4,751,436 | 10,755 | 11/03/21 |
Furlow Brenda S. | SVP - General Counse.. SVP - General Counsel | Sep 07 | Sell | 510.25 | 6,871 | 3,505,928 | 7,620 | 09/07/21 |
Furlow Brenda S. | SVP - General Counse.. SVP - General Counsel | Sep 07 | Option | 125.05 | 6,871 | 859,219 | 14,491 | 09/07/21 |
BAUMGARTNER ROBERT V | Director Director | Aug 25 | Option | 87.39 | 4,000 | 349,560 | 13,612 | 08/25/21 |
BAUMGARTNER ROBERT V | Director Director | Aug 25 | Sell | 485.27 | 4,000 | 1,941,080 | 9,612 | 08/25/21 |
Kummeth Charles R. | Chief Executive Offi.. Chief Executive Officer | Jun 16 | Sell | 449.6 | 7,481 | 3,363,458 | 166,904 | 06/16/21 |
Kummeth Charles R. | Chief Executive Offi.. Chief Executive Officer | Feb 18 | Option | 94.35 | 30,000 | 2,830,500 | 176,269 | 02/18/21 |
Eansor Norman David | President-Protein Sc.. President-Protein Sciences | Feb 09 | Option | 106.59 | 32,933 | 3,510,328 | 34,251 | 02/09/21 |
Eansor Norman David | President-Protein Sc.. President-Protein Sciences | Feb 09 | Sell | 381.75 | 32,933 | 12,572,173 | 1,318 | 02/09/21 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Jan 13 | Option | 106.59 | 10,000 | 1,065,900 | 19,137 | 01/13/21 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Jan 13 | Sell | 332.19 | 10,000 | 3,321,900 | 9,137 | 01/13/21 |
Furlow Brenda S. | SVP - General Counse.. SVP - General Counsel | Dec 02 | Sell | 302.1 | 10,857 | 3,279,900 | 6,124 | 12/02/20 |
Furlow Brenda S. | SVP - General Counse.. SVP - General Counsel | Dec 02 | Option | 106.59 | 11,795 | 1,257,229 | 16,981 | 12/02/20 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Nov 12 | Option | 106.59 | 10,991 | 1,171,531 | 16,528 | 11/12/20 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Nov 12 | Sell | 309.14 | 10,991 | 3,397,758 | 9,137 | 11/12/20 |
Kummeth Charles R. | Chief Executive Offi.. Chief Executive Officer | Nov 10 | Option | 86.25 | 25,157 | 2,169,791 | 186,644 | 11/10/20 |
STEER RANDOLPH C | Director Director | Nov 10 | Option | 68.63 | 10,000 | 686,300 | 15,112 | 11/10/20 |
STEER RANDOLPH C | Director Director | Nov 10 | Sell | 301.97 | 10,000 | 3,019,700 | 5,112 | 11/10/20 |
HIGGINS JOHN L | Director Director | Nov 10 | Option | 70.35 | 5,000 | 351,750 | 9,412 | 11/10/20 |
HIGGINS JOHN L | Director Director | Nov 10 | Sell | 299.96 | 5,000 | 1,499,800 | 4,412 | 11/10/20 |
Hippel James | Chief Financial Offi.. Chief Financial Officer | Nov 06 | Option | 108.49 | 15,909 | 1,725,967 | 17,946 | 11/06/20 |